This article is from the source 'bbc' and was first published or seen on . It will not be checked again for changes.

You can find the current article at its original source at http://news.bbc.co.uk/go/rss/-/1/hi/health/7142167.stm

The article has changed 2 times. There is an RSS feed of changes available.

Version 0 Version 1
'U-turn' over sight-saving drugs 'U-turn' over sight-saving drugs
(about 23 hours later)
A controversial decision to limit drugs for a major cause of blindness has been reversed by the NHS drug watchdog in England and Wales.A controversial decision to limit drugs for a major cause of blindness has been reversed by the NHS drug watchdog in England and Wales.
The National Institute for Health and Clinical Excellence (NICE) reconsidered its guidance after 13,000 complaints.The National Institute for Health and Clinical Excellence (NICE) reconsidered its guidance after 13,000 complaints.
It is now recommending that NHS patients with wet age-related macular degeneration should be eligible for 14 injections of Lucentis per eye.It is now recommending that NHS patients with wet age-related macular degeneration should be eligible for 14 injections of Lucentis per eye.
But a second drug, Macugen, is still not recommended for use on the NHS.But a second drug, Macugen, is still not recommended for use on the NHS.
Campaigners welcomed the decision, which comes after NICE carried out further "economic modelling" of the treatments.Campaigners welcomed the decision, which comes after NICE carried out further "economic modelling" of the treatments.
NICE has given thousands of people the best Christmas present they could wish for - hope that their sight might be saved Steve Winyard, RNIBNICE has given thousands of people the best Christmas present they could wish for - hope that their sight might be saved Steve Winyard, RNIB
Wet AMD, which affects the central part of the retina, is the leading cause of sight loss in the UK, and affects around a quarter of a million people, with 26,000 new cases each year.Wet AMD, which affects the central part of the retina, is the leading cause of sight loss in the UK, and affects around a quarter of a million people, with 26,000 new cases each year.
Both Macugen and Lucentis are from a class known as anti-VEGF drugs, which work by targeting a protein that protects against damage to the retina.Both Macugen and Lucentis are from a class known as anti-VEGF drugs, which work by targeting a protein that protects against damage to the retina.
Both drugs have already been made widely available in Scotland.Both drugs have already been made widely available in Scotland.
Additional dosesAdditional doses
In the first round of recommendations NICE said that Lucentis, the technical name for ranibizumab, should be made available only to patients in England and Wales with a particular type of wet AMD, which is responsible for about a fifth of all cases. In the first round of recommendations NICE said that Lucentis (ranibizumab) should be made available only to patients in England and Wales with a particular type of wet AMD, which is responsible for about a fifth of all cases.
Even then, it said the drug should be funded by the NHS only when both eyes were affected - and used only to treat the eye affected the least by the condition.Even then, it said the drug should be funded by the NHS only when both eyes were affected - and used only to treat the eye affected the least by the condition.
Under the latest proposals, which will undergo consultation, patients would be able to receive treatment when only one eye was affected.Under the latest proposals, which will undergo consultation, patients would be able to receive treatment when only one eye was affected.
NICE stated a maximum of 14 Lucentis injections per eye should be available - enough to treat most patients - but the manufacturer has agreed to pay for additional doses if needed.NICE stated a maximum of 14 Lucentis injections per eye should be available - enough to treat most patients - but the manufacturer has agreed to pay for additional doses if needed.
Also, the drug will no longer be limited to those with just one form of wet-AMD, although patients will become eligible only once their sight has deteriorated by a certain extent.Also, the drug will no longer be limited to those with just one form of wet-AMD, although patients will become eligible only once their sight has deteriorated by a certain extent.
The final guidance is due to be published in 2008.The final guidance is due to be published in 2008.
ThresholdThreshold
NICE Chief Executive Andrew Dillon said the new proposals with the manufacturer funding additional injections were a good use of NHS resources.NICE Chief Executive Andrew Dillon said the new proposals with the manufacturer funding additional injections were a good use of NHS resources.
Winfried Amoaku, chairman of the Royal College of Ophthalmologists' Scientific Committee, said he was relieved NICE had taken a fresh look at the recommendations.Winfried Amoaku, chairman of the Royal College of Ophthalmologists' Scientific Committee, said he was relieved NICE had taken a fresh look at the recommendations.
But he added that Macugen should also be available when treatment with Lucentis is problematic.But he added that Macugen should also be available when treatment with Lucentis is problematic.
"Clinicians should be free to choose the most suitable treatment for their patients.""Clinicians should be free to choose the most suitable treatment for their patients."
He added: "We think that the threshold at which treatment would start has been set too high."He added: "We think that the threshold at which treatment would start has been set too high."
RNIB's head of campaigns Steve Winyard also said they would like to see the eligibility threshold lowered.RNIB's head of campaigns Steve Winyard also said they would like to see the eligibility threshold lowered.
But he added: "NICE has given thousands of people the best Christmas present they could wish for - hope that their sight might be saved."But he added: "NICE has given thousands of people the best Christmas present they could wish for - hope that their sight might be saved."